HCV RNA Positivity among Hepatitis C Patients in Chongqing, China from 2004 to 2021: A Cross-Sectional Study

Author:

HE Yaping1,YE Shaodong2,ZHANG Wei1,LU Rongrong1,LIN Jing1,ZHOU Chao1,WU Guohui1

Affiliation:

1. Chongqing Municipal Center for Disease Control and Prevention

2. National Center for AIDS/STD Control and Prevention,China CDC

Abstract

Abstract

Background: A substantial number of Hepatitis C virus (HCV) infections have been identified, yet not all diagnosed patients have received treatment, leading to uncertainties in the progression of the virus within these individuals. This study aimed to assess the prevalence of HCV RNA positivity in diagnosed cases in Chongqing, China and identify key groups. Methods: An investigation was conducted on 6333 hepatitis C cases who were diagnosed and reported in the Chinese Disease Prevention and Control Information System in 17 districts of Chongqing, China from 2004 to 2021. The process involved collecting venous blood for HCV RNA and genotype testing, as well as gathering case information through a questionnaire. The analysis focused on comparing the HCV RNA positive rates among patients with different characteristics to identify key groups. Results: The HCV RNA positive rate was 37.7% among 6,333 cases. Patients who had never received treatment (47.6%) and those treated with interferon (25.6%) showed higher positivity rates than those treated with DAAs (8.1%). HCV RNA positive were generally higher in the following groups: males, aged 40-49 years and 50-59 years, farmers or manual laborers, the unemployed or job-seeking and cases diagnosed before 2019. Individuals with higher education level and higher income exhibited lower HCV RNA positivity rates. Conclusions: A considerable portion of identified hepatitis C cases in Chongqing remain HCV RNA positive. Multiple factors contribute to HCV RNA positivity among these patients, necessitating comprehensive interventions to promote adherence to treatment.

Publisher

Research Square Platform LLC

Reference37 articles.

1. WHO. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. Accountability for the global health sector strategies, 2016–2021. Geneva: World Health Organization; 2021.

2. World Health Organization. Hepatitis B and C in the WHO Western Pacific Region. https://www.who.int/westernpacific/health-topics/hepatitis/regional-hepatitis-data. (accessed 24 Dec 18, 2023).

3. Chinese Center for Disease Control and Prevention. The status of notifiable infectious diseases in China in 2020. http://www.nhc.gov.cn/jkj/s3578/202103/f1a448b7df7d4760976fea6d55834966.shtml (accessed Dec 18, 2023).

4. World Health Organization, Global Hepatitis, Report. 2017-New hepatitis data highlight need for urgent global response. 2017. https://www.who.int/news/item/21-04-2017-new-hepatitis-data-highlight-need-for-urgent-global-response (accessed Dec 18, 2023).

5. Hei FX, Ye SD, Ding GW et al. Epidemiological Analysis on Reported Hepatitis C Cases in China from 2012 to 2016. Biomed Environ Sci. 2018; 31(10):773–776. 10.3967/bes2018.103. PMID: 30423279.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3